An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Investigator: Eric Bernicker, MD

Study Coordinator: Lacey Burey

Status: Enrolling Number: NCT02741570

Phone: 713.441.1159

IRB Number: Pro00015388


The main purpose of this study is to compare nivolumab and ipilimumab with the Extreme study regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
More to Explore